2022
Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness
Lin C, Gou M, Pan S, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Luo X, Li CR, Zhang P, Huang J, Hong L, Tan Y. Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness. Neuroscience Letters 2022, 788: 136826. PMID: 35944595, DOI: 10.1016/j.neulet.2022.136826.Peer-Reviewed Original ResearchConceptsBrain cortical thicknessCognitive impairmentCognitive deficitsGray matter thicknessSchizophrenia (MATRICS) Consensus Cognitive BatteryAttention/vigilanceConsensus Cognitive BatteryCortical thicknessSerum Hcy levelsFirst-episode patientsHealthy controlsHigh homocysteineWorking memoryHcy levelsCognitive batteryNegative Symptom ScaleCognitive functionTreatment researchHigh-resolution magnetic resonance imagingSymptom ScaleSandwich enzyme-linked immunosorbentSchizophreniaHigher cortical thicknessImpairmentEnzyme-linked immunosorbent
2019
Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia
Tong J, Huang J, Luo X, Chen S, Cui Y, An H, Xiu M, Tan S, Wang Z, Yuan Y, Zhang J, Yang F, Li CR, Hong L, Tan Y. Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia. Brain Behavior And Immunity 2019, 81: 213-219. PMID: 31201848, PMCID: PMC6754783, DOI: 10.1016/j.bbi.2019.06.017.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) glutamate receptorsFirst-episode patientsNMDAR antibodiesAntibody levelsHealthy controlsSerum anti-NMDAR antibodyTotal scoreAnti-NMDAR antibodiesNMDAR antibody levelsNMDAR-antibody encephalitisElevated levelsReceptor antibody levelsSerum antibody levelsTreatment of schizophreniaPathogenesis of schizophreniaNegative Syndrome ScaleSymptoms of psychosisEnzyme-linked immunosorbentEtiology of schizophreniaMCCB total scoreAntibody encephalitisPatient groupNMDAR dysfunctionSchizophrenia (MATRICS) Consensus Cognitive BatteryGlutamate receptorsPlasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia
Xie T, Li Q, Luo X, Tian L, Wang Z, Tan S, Chen S, Yang G, An H, Yang F, Tan Y. Plasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia. Cognitive Neurodynamics 2019, 13: 357-365. PMID: 31354881, PMCID: PMC6624222, DOI: 10.1007/s11571-019-09530-3.Peer-Reviewed Original ResearchAttention/vigilanceSpeed of processingTotal antioxidant statusFirst-episode drug-naïve patientsDrug-naïve patientsCognitive impairmentCognitive deficitsSchizophrenia (MATRICS) Consensus Cognitive BatteryMCCB total scoreConsensus Cognitive BatteryHealthy controlsAntioxidant statusPlasma total antioxidant statusSex-matched healthy controlsOxidative stressPlasma TAS levelsPathophysiology of schizophreniaCognitive batteryStroop testNegative Syndrome ScaleReactive oxygen species-induced oxidative damageTreatment researchPsychopathological symptomsFEDN patientsHealthy subjects